Objective-Transplantation studies suggest that bone marrow cell ATP-binding cassette transporter A1 protects against atherosclerosis development. However, the in vivo effect of macrophage ATP-binding cassette transporter A1 expression on atherogenesis is not fully understood because bone marrow contains other leukocytes and hematopoietic stem and progenitor cells. Myeloid-specific ATP-binding cassette transporter A1 knockout mice in the low-density lipoprotein (LDL) receptor knockout C57BL/6 background were developed to address this question. Approach and Results-Chow-fed myeloid-specific ATP-binding cassette transporter A1 knockout/LDL receptor knockout (double knockout [DKO]) versus LDL receptor knockout (single knockout [SKO]) mice had similar plasma lipid concentrations, but atherogenic diet (AD)-fed DKO mice had reduced plasma very-LDL (VLDL)/LDL concentrations resulting from decreased hepatic VLDL triglyceride secretion. Resident peritoneal macrophages from AD-fed DKO versus SKO mice had significantly higher cholesterol content but similar proinflammatory gene expression. Atherosclerosis extent was similar between genotypes after 10 to 16 weeks of AD but increased modestly in DKO mice by 24 weeks of AD. Lesional macrophage content was similar, likely because of the higher monocyte flux through aortic root lesions in DKO versus SKO mice. After transplantation of DKO or SKO bone marrow into SKO mice and 16 weeks of AD feeding, atherosclerosis extent was similar and plasma apolipoprotein B lipoproteins were reduced in mice receiving DKO bone marrow. When differences in plasma VLDL/LDL concentrations were minimized by maintaining mice on chow for 24 weeks, DKO mice had modest, but significantly more, atherosclerosis compared with SKO mice.
A TP-binding cassette transporter A1 (ABCA1) is a membrane transporter that facilitates the movement of cellular free cholesterol (FC) and phospholipid across the plasma membrane to combine with apolipoproteins, principally apolipoprotein A-I, forming nascent high-density lipoprotein (HDL) particles that are subsequently converted in plasma to mature HDL. Studies have documented an inverse association between plasma HDL cholesterol (HDL-C) concentrations and cardiovascular disease (CVD) risk. 1 The apparent protective effect of elevated plasma HDL-C concentrations likely results from the role of HDL in facilitating macrophage reverse cholesterol transport. During reverse cholesterol transport, excess macrophage cholesterol in atherosclerotic plaques is effluxed to HDL particles, which then transport cholesterol back to the liver for excretion. 2, 3 Recent studies suggest that plasma HDL's capacity to efflux cholesterol better predicts prevalent CVD risk than static HDL-C concentrations. 4, 5 ABCA1 is a key transporter in facilitating macrophage reverse cholesterol transport. 6 Individuals with Tangier disease, a rare genetic disorder caused by functional mutations in ABCA1, have <5% of normal plasma HDL and massive storage of cholesteryl ester (CE) in macrophages throughout the body. Based on the Tangier disease plasma and macrophage lipid phenotype, one would predict increased CVD in these subjects. However, CVD is similar to controls in many Tangier subjects 7 and in animal models with global deficiency of ABCA1. 8, 9 This paradoxical finding is likely a result of the 50% decrease in plasma apolipoprotein B (apoB) lipoproteins (ie, very-low-density lipoprotein [VLDL] and low-density lipoprotein [LDL] ) that accompanies whole-body deficiency of ABCA1. Tissue-specific roles of ABCA1 expression on atherogenesis and CVD are difficult to determine because ABCA1 is expressed to a variable extent in nearly all tissues. 10 In particular, the presumed atheroprotective role of macrophage ABCA1, based primarily on the well-accepted function of ABCA1 to stimulate macrophage FC efflux, lacks sufficient supporting evidence.
Attempts to identify and isolate the role of macrophage ABCA1 in atherosclerosis development have relied on bone marrow (BM) transplantation experiments to date. Several such studies have uniformly identified an atheroprotective role for hematopoietic ABCA1. 8, [11] [12] [13] [14] [15] Nevertheless, BM contains multiple cell populations, many of which have been implicated in atherogenesis. For instance, hematopoietic stem and progenitor cells, 16 T and B lymphocytes, 17, 18 natural killer cells, 19 and dendritic cells 20 all may affect atherosclerosis, making it difficult to distinguish the specific contribution of macrophage ABCA1 expression to atherogenesis.
To define the role of macrophage ABCA1 expression in atherosclerosis, we generated myeloid (ie, macrophage and neutrophil) cell-specific ABCA1 knockout (MSKO; ie, B6.129P2-Lyzs tm1(cre)Ifo /J-Abca1 flox/flox ) mice. 21 Macrophages from these mice have defective FC efflux and respond to Tolllike receptor agonists with an exaggerated production of inflammatory cytokines. 21 An initial study using these mice crossed into the LDL receptor knockout (LDLrKO; ie, Ldlr tm1Her /J) background suggested a minimal role for myeloid cell-specific ABCA1 in atherogenesis, 22 in contrast to other reports. 8, [11] [12] [13] [14] [15] However, this study only measured effects at 1 time point of AD feeding (16 weeks) and used MSKO/LDLrKO mice in a mixed genetic background (90% C57BL/6, 10% 129 SvEV). Because 129 mice strains are resistant to atherosclerosis relative to C57BL/6 mice, 23 the 10% 129 SvEV background in MSKO/LDLrKO mice may have lessened atherogenesis. Thus, results of our previous study did not definitively elucidate the role of macrophage ABCA1 in atherogenesis.
To address this deficiency, we have backcrossed MSKO/ LDLrKO mice to >99% in the C57BL/6 background and investigated early-to late-stage atherosclerosis progression. Myeloid cell-specific deletion in AD-fed LDLrKO mice did not result in the expected increase in atherosclerosis relative to LDLrKO mice, because of a considerable reduction in plasma apoB lipoprotein concentrations in MSKO/LDLrKO mice, resulting from reduced hepatic VLDL triglyceride production. However, when differences in plasma apoB lipoprotein concentrations between genotypes of mice were minimized by maintaining mice on a chow diet, expression of myeloid cell ABCA1 was atheroprotective.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Myeloid-Specific ABCA1 Deletion Reduces Plasma Lipids in AD-Fed LDLrKO Mice
To study atherosclerosis development in a stage-specific manner (ie, early to advanced), MSKO/LDLrKO and LDLrKO mice were switched from chow at 7 to 9 weeks of age to an AD for 10, 16, or 24 weeks with periodic measurements of total plasma cholesterol (TPC), FC, and triglyceride levels during disease progression. Chow-fed (ie, baseline) MSKO/ LDLrKO and LDLrKO mice displayed similar plasma lipid concentrations ( Figure 1A and 1B; 0 weeks), consistent with previous results from chow-fed MSKO and wild-type mice. 21 Two weeks of AD consumption increased TPC and FC concentrations in both genotypes, but the increase was significantly attenuated in MSKO/LDLrKO mice throughout the 16-week disease progression phase (area under curve; P<0.05; Figure 1A and 1B). Plasma triglyceride concentrations varied little during AD feeding but were lower in MSKO/LDLrKO versus LDLrKO mice ( Figure 1A and 1B). Fast protein liquid chromatography fractionation of plasma showed that lipoprotein cholesterol distribution was similar for both groups of chow-fed mice ( Figure 1C ). However, after 16 weeks of AD feeding, plasma VLDL cholesterol and LDL cholesterol concentrations were significantly lower for both sexes of MSKO/LDLrKO mice relative to their LDLrKO counterparts ( Figure 1D ; Table I in the online-only Data Supplement). Collectively, these results suggest a novel role for myeloid cell ABCA1 in apoB lipoprotein metabolism under atherogenic hyperlipidemia conditions and further support its minimal contribution to the plasma HDL pool. 21
VLDL Triglyceride Secretion Is Decreased in AD-Fed MSKO/LDLrKO Mice
To determine the potential mechanism for decreased plasma apoB lipoprotein concentrations in AD-fed MSKO/LDLrKO mice, we measured plasma triglyceride accumulation in vivo using the Triton block procedure, which we use as a surrogate for VLDL triglyceride secretion. VLDL triglyceride mass accumulation was significantly reduced in MSKO/LDLrKO versus Figure  IV in the online-only Data Supplement), suggesting that local cytokine production from Kupffer cells was not reducing hepatic VLDL triglyceride production in MSKO/LDLrKO mice. Food intake, fractional cholesterol absorption, and fecal neutral sterol were also similar between genotypes of mice ( Figure V in the online-only Data Supplement). Overall, these data suggest a novel role for myeloid cell ABCA1 in inducing VLDL triglyceride production during atherogenesis in LDLrKO mice.
Macrophage ABCA1 Deletion Results in Massive Cellular Cholesterol Accumulation
Macrophage ABCA1 is critical in preventing excess cellular cholesterol accumulation. 21, 24 To determine the degree of in vivo macrophage cholesterol accumulation during atherosclerosis progression, we measured cellular cholesterol content in resident peritoneal macrophages (PMs). Despite the significant reduction of plasma apoB lipoprotein in MSKO/LDLrKO mice, PMs from these mice had dramatically higher TC, FC, and CE content after 16 weeks of AD feeding compared with LDLrKO mice (732 versus 9 μg CE/mg protein in female mice; P<0.01; Figure 3A ). A similar trend was observed for 16-week AD-fed male mice (data not shown) and female mice fed the AD for 24 weeks, with even greater differences between genotypes (1496 versus 48 μg TC/ mg protein in female mice; P<0.01; Figure 3B ). Resident PM ATP-binding cassette transporter G1 (Abcg1) gene expression was similar for both genotypes of mice (data not shown). These data suggest that PM ABCA1 deficiency results in massive CE accumulation that is progressive in the face of continued but stable hyperlipidemia ( Figure 1 ) and that no other macrophage cholesterol efflux system can compensate for ABCA1 loss for an extended (10-24 weeks) period of hyperlipidemia.
ABCA1 Deletion in Myeloid Cells Results in Comparable Plasma Cytokine Levels
Macrophages lacking ABCA1 expression secreted more proinflammatory cytokines on Toll-like receptor 4 stimulation with lipopolysaccharide compared with wild-type macrophages. 21, 24 Dietary saturated fatty acids also activate Toll-like receptor 4 signaling in vitro and in vivo. 25 To determine whether AD-fed MSKO/LDLrKO mice exhibit greater chronic lowgrade inflammation in vivo than LDLrKO mice, we examined plasma cytokine protein expression semiquantitatively using a cytokine array. Plasma proinflammatory cytokine and chemokine levels appeared similar between genotypes of mice fed chow or the AD for 16 or 24 weeks ( Figure VIA in the online-only Data Supplement), suggesting that in vivo inflammatory response was not enhanced in MSKO/LDLrKO mice. In addition, proinflammatory gene expression in resident PMs was similar between MSKO/LDLrKO and LDLrKO mice fed the AD for 10, 16, or 24 weeks ( Figure VIB in the online-only Data Supplement). These data suggest that the combination of AD and resulting hyperlipidemia did not result in an exacerbated inflammatory state in vivo in MSKO/LDLrKO versus LDLrKO mice during atherosclerosis progression.
Myeloid-Specific ABCA1 Deficiency Does Not Affect Blood Leukocyte Distribution
Previous studies have suggested that deletion of BM cell ABC transporters (ABCA1 and ABCG1) results in blood monocytosis, neutrophilia, and increased numbers of Ly6-C hi monocytes, likely through increased expansion of hematopoietic stem and multipotential progenitor cells. 16 Transplantation of BM from myeloid cell-specific ABCA1 and ABCG1 double knockout (DKO) donor mice into LDLrKO recipient mice resulted in monocytosis and neutrophilia when mice were 
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fed a Western-type diet and neutrophilia when fed chow. 26 In our study, the distribution of blood leukocytes was similar for both genotypes of chow-and AD-fed mice ( Figure VII in the online-only Data Supplement). The different outcome may be attributed to more restrictive deletion of ABC transporters (ie, ABCA1 only). In addition, the anticipated increase in the percentage of Ly6-C hi monocytes that accompanies dietinduced hyperlipidemia occurred and was similar for MSKO/ LDLrKO and LDLrKO mice ( Figure VIIE in the online-only Data Supplement).
Myeloid-Specific ABCA1 Deficiency Enhances Advanced, But Not Early or Intermediate, Atherogenesis
We evaluated the effect of myeloid ABCA1 expression on atherosclerosis development using several measurements. MSKO/ LDLrKO and LDLrKO mice fed the AD for 10 weeks or 16 weeks had similar levels of aortic TC, FC, and CE content, although FC concentrations were slightly, but significantly, lower for 10-week diet-fed MSKO/LDLrKO mice ( Figure 4A and 4B). After 24 weeks of AD, aortic TC and FC levels were increased in MSKO/LDLrKO mice relative to LDLrKO mice and CE was higher on average ( Figure 4C ). Aortic root lesions stained with Oil red O were comparable in size for both genotypes of mice fed the AD for 16 weeks ( Figure 4D and 4E), supporting the aortic cholesterol measurements. In addition, no significant differences were observed in lesional macrophages ( Figure 4F 
Myeloid-Specific ABCA1 Deficiency Significantly Increases Monocyte/Macrophage Flux Through Atherosclerotic Lesions
Macrophage ABCA1 has been implicated previously in chemotaxis. 27, 28 The massive cholesterol accumulation in MSKO/ LDLrKO resident PMs and similar extent of aortic cholesterol accumulation between genotypes of mice led us to speculate that fewer macrophages accumulate in MSKO/LDLrKO mouse atherosclerotic lesions, assuming PMs are phenotypically similar to aortic lesional macrophages. However, aortic root lesional macrophage content, measured by CD68 staining, was similar between genotypes ( Figure 4F and 4G). In vivo recruitment of fluorescent bead-labeled monocytes to aortic root lesions was measured for a 5-day period after 16 weeks of diet-induced atherogenesis, and surprisingly, we found a 4-fold increase in the number of monocytes recruited into MSKO/LDLrKO versus LDLrKO mouse lesions ( Figure 5A ), compatible with previous studies showing increased in vitro and in vivo chemotaxis of ABCA1deficient macrophages. 27, 29 The extent of apoptosis in atherosclerotic lesions was similar for both genotypes of mice ( Figure 5B ). We then repeated the monocyte recruitment study and examined aortic root lesional bead content 5 and 28 days after fluorescent bead labeling. Blood monocyte bead labeling efficiency 24 hours after bead injection was similar for both genotypes of mice ( Figure IXA in the online-only Data Supplement). Consistent with the first study ( Figure 5A ), significantly more beads were observed in lesions of MSKO/LDLrKO versus LDLrKO mice 5 days (baseline) after labeling ( Figure 5C ). However, sustained lesion progression from 5 to 28 days after bead injection resulted in increased bead accumulation in LDLrKO but not in MSKO/LDLrKO mice ( Figure 5C ). The increase in bead labeling between 5 and 28 days in LDLrKO mice likely resulted from low but measurable bead-labeled monocytes remaining in blood after 5 days. 30 Similar trends were observed using total number of beads per section, without normalizing to blood monocyte bead labeling efficiency ( Figure IXB and IXC in the online-only Data Supplement). The lower bead content of aortic lesions from MSKO/LDLrKO mice at 28 days may have occurred through egress of bead-labeled cells, counterbalancing the greater influx, resulting in similar steady-state aortic root macrophage content in MSKO/LDLrKO and LDLrKO mice.
To explore this idea further, we examined whole aorta gene expression. As anticipated, ABCA1 expression was significantly lower in MSKO/LDLrKO aortas, suggesting that macrophage gene expression likely dominated overall aortic gene expression. We also observed significantly decreased CD11c expression in MSKO/LDLrKO versus LDLrKO mice but similar F4/80 expression ( Figure 5D ), suggesting that dendritic cell content may be reduced in MSKO/LDLrKO aortas. In a separate experiment, we analyzed cells isolated from aortic digests of mice fed the AD for 34 weeks and observed a trend toward decreased CD11c+ cells in MSKO/LDLrKO versus LDLrKO mice ( Figure 5E ). Because dendritic cells migrate to peripheral lymph nodes for antigen presentation, we measured peripheral lymph node CD11c content in mice used for the second bead labeling experiment and observed a significantly increased percentage of CD11c+ and Ly6C hi -CD11c+ cells at 5 ( Figure 5F ) and 28 ( Figure 5G ) days after bead injection in MSKO/LDLrKO mice. The combined results are compatible with the interpretation that MSKO/LDLrKO monocytes flux through atherosclerotic lesions at a greater rate than LDLrKO monocytes.
Similar Extent of Atherosclerosis in LDLrKO Mice Transplanted With MSKO/LDLrKO or LDLrKO BM
Previous BM transplantation studies uniformly found a significant atheroprotective role of hematopoietic ABCA1, and macrophage ABCA1 expression was assumed to mediate this effect. However, AD-fed MSKO/LDLrKO mice did not display accelerated atherosclerosis under similar conditions (ie, AD for 10 or 16 weeks). To determine whether the different outcomes were attributable to different experimental strategies or a more specific deletion of ABCA1, we transplanted male MSKO/ LDLrKO (DKO) The plasma phenotype of BM transplant mice resembled that of the nontransplanted counterparts in the 16 weeks of atherosclerosis experiment (Figure 1 ). TPC and plasma triglyceride levels in DKO BM recipients were ≈40% to 50% lower than those of SKO BM recipients as soon as 2 weeks after initiation of the AD and remained lower throughout the 16-week progression phase ( Figure 6A ). There was only a 5% difference in basal TPC (ie, chow diet) with indistinguishable cholesterol distribution among lipoproteins ( Figure 6B , time 0), whereas VLDL cholesterol and LDL cholesterol contributed to the decreased TPC in AD-fed DKO BM recipient mice ( Figure 6B, 2-16 weeks) . In agreement with the nontransplant 16-week study, cholesterol content of resident PMs was greatly increased ( Figure 6C ), but whole aorta cholesterol content was similar between DKO versus SKO BM recipient mice ( Figure 6D ). These data suggest that the difference in outcome between our study and previous BM Figure 5 . Monocyte recruitment and lesional monocyte/macrophage flux. Fluorescent beads were intravenously injected into 15-week atherogenic diet (AD)-fed female mice to label monocytes. One day later, a blood sample was taken to quantify blood monocyte labeling efficiency and specificity by flow cytometry. A, Five days after bead injection, mice were euthanized, hearts were harvested and frozen in Optimal Cutting Temperature compound, frozen sections were cut (8 μm), and the number of fluorescent beads in aortic root intima was quantified manually and normalized to blood monocyte labeling efficiency. B, Aortic root sections from 16-week AD-fed female mice were immunostained with cleaved caspase 3 for apoptotic cell quantification. C, Lesional monocyte/macrophage flux was evaluated by comparing bead-labeled monocyte accumulation 5 and 28 days after intravenous fluorescent bead injection. D, Gene expression in whole aortas of mice from monocyte/macrophage flux study (C). E, Flow cytometry analysis of aortas from male mice fed the AD for 34 weeks (n=4-6). F and G, Flow cytometry analysis of peripheral lymph node cells from monocyte flux study mice (n= 3-4 for 5-day data, F; n=4-6 for 28-day data, G). Data are expressed as mean±SEM. *P<0.05. ABCA1 indicates ATP-binding cassette transporter A1; ABCG1, ATPbinding cassette transporter G1; CX3CR1, CX3C chemokine receptor 1; CCR, C-C chemokine receptor; IL-10, interleukin 10; LDLrKO, low-density lipoprotein receptor knockout; MCP-1, monocyte chemoattractant protein-1; MSKO, myeloid-specific ABCAI knockout; SR-BI, scavenger receptor class B type 1; TC, total cholesterol; TNFα, tumor necrosis factor-α; and UNC5B, UNC-5 homolog B.
transplantation studies is because of the more restrictive myeloid cell ABCA1 deletion in our study.
Chow Diet-Fed MSKO/LDLrKO Mice Are More Susceptible to Early-Stage Atherogenesis
The finding that AD-fed MSKO/LDLrKO mice had similar early and intermediate atherosclerosis compared with LDLrKO mice, but lower plasma VLDL and LDL concentrations and higher macrophage cholesterol content, led us to hypothesize that the deleterious effects of ABCA1 deletion in macrophages were offset by the substantial reduction of plasma atherogenic apoB lipoprotein. To test this possibility, we fed female mice chow until they were 24 weeks old to minimize the differences in plasma lipids and lipoproteins observed with AD feeding. This time course was similar to the previously described 16-week AD study (16 weeks of AD feeding starting at 8 weeks of age) using mice with and without BM transplantation. As anticipated, chow-fed MSKO/LDLrKO versus LDLrKO mice had similar TPC and plasma triglyceride concentrations over time ( Figure 7A and 7B) . Although the chow-fed MSKO/LDLrKO mice had significantly lower TPC concentrations compared with chow-fed LDLrKO mice, the difference was minimal (≈6% to 17%) throughout the study and likely achieved statistical significance because of the low variability in measurements. Plasma lipoprotein cholesterol distribution of 12-week-old mice revealed minor differences between genotypes, with LDL cholesterol and HDL-C being slightly decreased in MSKO/ LDLrKO mice (2.93 versus 2.61 mmol/L LDL cholesterol; 1.11 versus 0.94 mmol/L HDL-C; Figure 7C ). Resident PMs without ABCA1 expression exhibited 1.5-and 3-fold increases in cellular FC and TC content, respectively, and a striking 70-fold induction in CE accumulation (≈1 versus 71 μg CE/mg protein in female mice; P<0.05) under mild hyperlipidemic conditions ( Figure 7D) . A similar trend was present in male mice (data not shown). Whole aorta chemical analysis by gas-liquid chromatography showed low, but detectable, amounts of cholesterol compared with AD-fed mice. A significant ≈70% higher aortic CE content (0.77 versus 1.31 μg CE/ mg protein; P<0.05) in MSKO/LDLrKO mice suggests increased early-stage atherosclerosis compared with LDLrKO mice (Figure 7E ). Aortic root Oil red O-stained sections from representative animals of each group showed ≈74% larger lesions for MSKO/LDLrKO versus LDLrKO mice (0.0299 versus 0.0519 mm 2 ; P=0.0227; Figure 7F ). Collectively, these results suggest that in the absence of major differences in plasma lipid concentrations, deletion of myeloid cell ABCA1 enhanced early atherosclerotic lesion development. These results support the conclusion that less atherogenic lipid profiles may counterbalance the proatherogenic effects present in MSKO/LDLrKO mice, preventing the expected increase in early-/intermediate-stage atherogenesis.
Discussion
Macrophages are a major cellular constituent of atherosclerotic lesions and are involved in the uptake and breakdown of modified lipoproteins. 31 This process can result in the formation of CE-enriched macrophages or foam cells. ABCA1 and other cholesterol export proteins (eg, ABCG1 and scavenger receptor class B type 1) counterbalance the unregulated accumulation of macrophage CE by effluxing excess cellular cholesterol. 32 Studies using whole-body ABCA1 knockout mouse BM suggest that genetic deletion of hematopoietic Abca1 uniformly increases atherosclerosis. 8, [11] [12] [13] However, the role of macrophage ABCA1 in atherosclerosis development has never been formally tested, because BM used for transplantation studies contains other cell populations that are likely important in atherosclerosis progression. 33 We addressed this question by performing atherosclerosis studies using mice with genetic deletion of Abca1 in leukocytes of myeloid lineage crossed into the Ldlr C57BL/6 background (ie, MSKO/LDLrKO).
Contrary to expectation, AD-fed MSKO/LDLrKO mice did not have accelerated atherosclerosis relative to LDLrKO mice at early and intermediate time points because of an unanticipated decrease in plasma VLDL and LDL concentrations. Only advanced atherosclerosis (24 weeks of AD feeding) was modestly, but significantly, increased in MSKO/LDLrKO mice. Similar atherosclerosis (ie, SKO and DKO not different) and plasma lipoprotein (ie, lower VLDL/LDL for DKO mice) results were obtained for intermediate-stage atherosclerosis (ie, 16 weeks) using transplantation of SKO and DKO BM into LDLrKO recipient mice, suggesting that our unique finding was not because of a different study design compared with previous BM transplantation studies. We hypothesize that the negative impact of myeloid cell ABCA1 deletion in vivo was offset by an atheroprotective reduction in plasma VLDL and LDL, significantly delaying (16 to 24 weeks) and minimizing the anticipated increase in atherosclerosis in MSKO/LDLrKO versus LDLrKO mice. In support of this hypothesis, minimizing the difference in plasma VLDL and LDL by maintaining mice on a chow diet resulted in a modest, but significant, increase in atherosclerosis in MSKO/LDLrKO mice. Overall, our study results suggest that myeloid ABCA1 expression is atheroprotective in similar states of hyperlipidemia and has a novel function in controlling plasma VLDL and LDL concentrations and in vivo monocyte trafficking during atherogenesis (see below). This is the first atherosclerosis study using MSKO/LDLrKO mice backcrossed into the C57BL/6 background. Brunham et al 22 previously reported that atherosclerosis development was similar for MSKO/LDLrKO and LDLrKO mice fed an AD for 16 weeks, in agreement with our results (Figure 4 ). However, mice used in that study were in a mixed genetic background (≈90 C57BL/6, ≈10% 129 SvEV), and because the 129 background is atherosclerosis-resistant, 23 these results may have been influenced by the background effects. In addition, previous BM transplantation studies using different study designs (ie, diets: chow, Western, Paigen; genetic backgrounds: apolipoprotein E KO, LDLrKO) uniformly observed a 1.4-to 1.8-fold increase in early-to intermediate-stage (10-14 weeks of diet feeding) atherosclerosis development. 8, [11] [12] [13] [14] In 2 studies, atherosclerosis increased 40% to 60% despite significantly reduced plasma cholesterol concentrations. 11, 13 The atheroprotective effect of ABCA1 observed was mainly attributed to macrophage ABCA1. However, our results, using a more restrictive deletion of ABCA1 in BM cells of myeloid origin, showed no difference in atherosclerosis at early (10 weeks) and intermediate (16 weeks) stages of progression. The different outcomes may have arisen from distinct experimental strategies (ie, BM transplantation versus myeloid cell-specific gene targeting) or the relative contribution of nonmyeloid BM versus myeloid cell ABCA1 expression in atherogenesis. The first possibility was eliminated when we found similar atherosclerosis and plasma lipoprotein outcomes between our nontransplant study and our BM transplantation study using AD-fed LDLrKO recipient mice transplanted with MSKO/LDLrKO or LDLrKO BM. The significantly accelerated atherosclerosis development in earlier studies is likely a result of the impact of ABCA1 expression on nonmyeloid BM cells, because more specific deletion of ABCA1 in only myeloid cells under similar experimental conditions failed to exacerbate atherogenesis during the same time frame.
Macrophages (PM-and BM-derived macrophages) from chowfed MSKO mice have defective FC and PL efflux. 21 Although CE accumulation is minimal in chow-fed MSKO mouse macrophages, FC is significantly elevated (≈10%), leading to increased membrane lipid raft content and hyperresponsiveness to proinflammatory agents such as lipopolysaccharide. Previous studies showed that macrophage FC efflux is facilitated by ABCA1, ABCG1, SR-BI, and aqueous diffusion. 6 In the hyperlipidemic background of LDLr deficiency, resident MSKO PMs had massive CE accumulation that increased in severity from early to late stages of atherogenesis. Even chow-fed MSKO/LDLrKO mice had elevated resident PM CE content. However, despite the massive cholesterol loading in resident MSKO/LDLrKO PMs, inflammatory gene expression was similar to that of LDLrKO macrophages ( Figure VIB in the online-only Data Supplement). This outcome likely results from Liver X receptor-mediated downregulation of inflammatory gene expression by desmosterol as described by Spann and colleagues. 34 Our data document that loss of myeloid cell ABCA1 expression in AD-fed LDLrKO mice results in progressive accumulation of PM CE, although plasma lipoprotein concentrations were relatively stable after 2 weeks of AD feeding (Figure 1 ), suggesting that no other efflux mechanism can compensate for loss of PM ABCA1 in vivo to prevent massive macrophage CE accumulation.
Another novel finding in the present study was that plasma VLDL and LDL concentrations were ≈50% lower in AD-fed MSKO/LDLrKO versus LDLrKO mice, suggesting an in vivo role for macrophage ABCA1 expression in regulating plasma apoB lipoprotein metabolism during atherogenesis. Similar observations were made in 2 BM transplantation studies after global ABCA1 knockout versus wild-type BM was transplanted into LDLrKO mice. 11, 13 Although the 2 BM transplantation studies did not address this finding with additional experiments, herein we show that reduced hepatic triglyceride content, reduced hepatic VLDL triglyceride secretion, and lower plasma nonesterified fatty acid concentrations may contribute to lower plasma VLDL in AD-fed MSKO/LDLrKO mice. Because cytokines can modulate lipid metabolism 35 and macrophages are an important source of cytokines, decreased hepatic VLDL triglyceride secretion in AD-fed MSKO/LDLrKO mice may result from macrophage cytokine production, either locally (ie, Kupffer cells) or systemically. Acute ablation of Kupffer cells did not normalize the differences in TPC and plasma triglyceride between genotypes of mice ( Figure IV in the online-only Data Supplement), suggesting that resident hepatic macrophages were not affecting hepatic lipogenesis and triglyceride secretion. The fact that the plasma lipid phenotype in our BM transplantation study recapitulated the 16 weeks of AD study also suggests that circulating leukocytes and hematopoietic stem and progenitor cells may affect hepatic lipid metabolism, because Kupffer cells are not efficiently deleted from the liver during the time course of the BM transplantation study. 36, 37 The underlying mediators and mechanisms responsible for decreased hepatic triglyceride production in AD-fed MSKO/LDLrKO mice are unknown and will require additional studies to identify.
Hyperlipidemic mouse models (ie, LDLrKO and apolipoprotein E KO) exhibit monocytosis and increased trafficking of monocytes into atherosclerotic lesions when fed cholesterolcontaining ADs. 38, 39 We also observed similar AD-induced blood Ly6C hi monocytosis for both genotypes of mice ( Figure VIIE in the online-only Data Supplement). Furthermore, monocyte flux through atherosclerotic lesions was significantly increased in MSKO/LDLrKO mice ( Figure 5 ). Subsequent analysis of aortic gene expression and lymph node cells suggested that monocytes from MSKO/LDLrKO mice enter lesions more rapidly, convert to dendritic-like cells (ie, CD11c+), and exit lesions more rapidly than their LDLrKO counterparts. This concept is supported by decreased aortic CD11c expression and increased lymph node CD11c+, Ly6C hi cells. Macrophage ABCA1 deficiency enhances chemotaxis in vitro and in vivo in chow-fed mice, 29 and our results in AD-fed MSKO/LDLrKO mice provide additional in vivo evidence of this effect. However, because aortic bead content progressed between 5 and 28 days in LDLrKO mice, but not in MSKO/LDLrKO mice ( Figure 5C ), there may be alternative explanations that require cautious interpretation of our monocyte flux data. For instance, we observed similar blood monocyte bead labeling for both genotypes of mice 1 day after intravenous bead injection, but residual monocyte labeling may differ between genotypes between 5 and 28 days. In addition, MSKO/LDLrKO monocyte influx into lesions may decrease between 5 and 28 days after bead injection, resulting in decreased influx and not necessarily increased egress from lesions. However, these limitations notwithstanding, we think that the sum total of evidence suggests strikingly different in vivo trafficking of monocytes in and out of atherosclerotic lesions in MSKO/LDLrKO versus LDLrKO mice.
In our study, resident PMs from MSKO/LDLrKO mice were massively loaded with cholesterol compared with LDLrKO mice, yet aortic lesions were similar in cholesterol content, Oil red O staining, and macrophage number, suggesting that resident PMs and macrophages in atherosclerotic lesions are phenotypically different. It is not likely that aortic lesional macrophages had reduced cholesterol content as a result of upregulation of alternative efflux pathways because aortic ABCG1 and SR-BI mRNA expression was similar for both genotypes of mice ( Figure 5D ). Recent studies suggest that monocyte recruitment to atherosclerotic lesions primarily contributes to macrophage accumulation in early lesion development, but local proliferation of lesional macrophages predominates in advanced atherosclerotic lesions. [40] [41] [42] Thus, it may not be surprising that resident PMs do not phenocopy aortic macrophages in intermediate to advanced stages of atherosclerosis and are not good surrogates for aortic lesional macrophages. Attempts to isolate F4/80+cells from aortas of mice fed the AD for 20 weeks using fluorescence-activated cell sorting failed to yield sufficient cells for mass spectrometric quantification of FC and CE. Considering the likely distinct differences in local environment where macrophages reside (ie, peritoneal cavity versus atherosclerotic plaque), characterization of lesional macrophages, although difficult to approach, and the underlying mechanisms of altered monocyte/macrophage trafficking merit further investigation.
In conclusion, we investigated the effects of myeloid cellspecific ABCA1 deletion on early to advanced stage atherosclerosis development. Myeloid cell ABCA1 expression seemed to be modestly atheroprotective in chow-fed mice, in which plasma lipid changes are minimal, but its atheroprotective effect was eliminated or significantly delayed in AD-fed LDLrKO mice because of a paradoxical decrease in plasma VLDL and LDL concentrations, resulting from decreased hepatic production of VLDL triglyceride. Our findings also indirectly support an atheroprotective role for ABCA1 expression in nonmyeloid cells (ie, BM hematopoietic stem and progenitor cell, T cells) in atherogenesis, given the difference in atherosclerosis outcome in BM transplantation studies using MSKO/LDLrKO versus global ABCA1 knockout BM. Finally, this study highlights the multifaceted impact of myeloid ABCA1 expression on atherogenesis and lipoprotein metabolism and the complex patterns of atherosclerosis progression.
